Throughout the last three months, 4 analysts have evaluated Collegium Pharmaceutical (NASDAQ:COLL), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
0
0
1
0
0
1M Ago
1
0
0
0
0
2M Ago
0
0
0
0
0
3M Ago
1
1
0
0
0
Analysts have set 12-month price targets for Collegium Pharmaceutical, revealing an average target of $39.5, a high estimate of $40.00, and a low estimate of $39.00. Surpassing the previous average price target of $37.67, the current average has increased by 4.86%.
Interpreting Analyst Ratings: A Closer Look
The standing of Collegium Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
David Amsellem
Piper Sandler
Maintains
Neutral
$39.00
$39.00
Serge Belanger
Needham
Maintains
Buy
$40.00
-
Les Sulewski
Truist Securities
Raises
Buy
$40.00
$37.00
David Amsellem
Piper Sandler
Raises
Overweight
$39.00
$37.00
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Collegium Pharmaceutical. This insight gives a snapshot of ...Full story available on Benzinga.com
Benzinga
